Osteoarthritis
Tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee
This report has been verified
by one or more authors of the
original publication.
Osteoarthritis Cartilage; 2011;19(12):1405-1412
83 Japanese patients with moderate to severe osteoarthritis of the knee were randomized to receive either tanezumab 10, 25, 50, 100 or 200 mg/kg or a placebo. The results from 120 day follow-up indicated that stronger doses of tanezumab result in significantly better pain relief in comparison to baseline measurements. However, the results from the study also indicated that adverse events occurred in 6 patients who received the drug in comparison to 1 who received placebo.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
